Cryoport Systems Announces Major Expansion of Pont-du-Château Facility and Official Rebrand of Cell&Co
NASHVILLE, Tenn., June 12, 2024 – Cryoport Systems, a global leader in temperature-controlled supply chain solutions for the life sciences industry, is excited to announce the significant expansion of its Pont-du-Château facility in France. This development increases the facility’s size from 445 m² to 1040 m², enhancing its BioServices and biostorage capabilities. Concurrently, this expansion marks the official rebrand of Cell&Co BioServices to Cryoport Systems, solidifying its integration into Cryoport’s global operations.
Global Experts, Local Presence
Cryoport Systems continues to expand its reach across Europe, bringing its world-class temperature-controlled supply chain solutions closer to the rapidly growing market for advanced therapies. Our growing footprint is Enabling the Outcome™ for biopharmaceutical research and development across Europe, supporting the delivery of critical therapies from initial research to global commercialization. By expanding our presence, we provide additional services and capacity straight to the heart of Europe, supporting the rapid growth of advanced therapies in the region.
Enhanced Capabilities at Pont-du-Château
The expanded facility now supports a broader range of services, significantly boosting its storage capacity and operational capabilities:
- Secondary Packaging Services: The facility now includes capabilities for secondary packaging of commercial and clinical products, augmenting its existing storage solutions.
- Increased Storage Capacity: A new -20°C walk-in storage room offers substantial space for storing additional temperature-sensitive materials.
- New Refill-In Station: A dedicated area for refilling shippers improves logistics efficiency.
- Optimized Workflow: Separate shipping and reception areas, along with an isolated control area, enhance operational efficiency and security.
- Centralized Technical Equipment: All technical equipment is centralized in an isolated room with a fire prevention system, significantly increasing site safety.
- Expanded Office Space: New office areas support the increased operational capacity of the site.
Rebranding to Cryoport Systems
This expansion also marks the official rebranding of Cell&Co BioServices as Cryoport Systems. Acquired in April 2022, Cell&Co has been a pivotal part of Cryoport Systems’ growth in the EMEA region. This rebrand aligns with Cryoport Systems’ strategic vision and reinforces its global presence.
“We are thrilled to announce the expansion of our Pont-du-Château facility and the official rebranding of Cell&Co,” said Mark Sawicki, CEO of Cryoport Systems. “These advancements reflect our dedication to providing the highest standards of service and innovation in temperature-controlled supply chain solutions. The enhanced capabilities of the Pont-du-Château site position us to better serve the life sciences industry and support the development and delivery of critical therapies worldwide.”
Commitment to Quality and Innovation
The expanded Pont-du-Château facility continues to deliver comprehensive GMP biorepository services, clinical trial supply services (including importation, QP services, secure storage, drug packaging and labelling, and distribution), and commercial supply services. This expansion enhances Cryoport Systems’ ability to support the pharmaceutical and biotech industries with high-quality BioServices, reflecting our commitment to advancing the growing market for advanced therapies across Europe.
Cryoport Systems is strategically expanding its European presence with our established facilities in The Netherlands and multiple locations in France, including Clermont-Ferrand and the newly expanded Pont-du-Château facility. Additionally, we will soon launch a Global Supply Chain Hub in Stevenage, UK, and a Cryopreservation Center in Villers-le-Bouillet, Belgium. These developments demonstrate our proactive approach to meeting the evolving needs of the European market and building the necessary infrastructure to support the growth of advanced therapies across the region. Together, these efforts solidify our commitment to delivering unparalleled support to our clients and advancing the future of biopharmaceutical innovations in Europe.
Cryoport Systems is Enabling the Outcome™ for advanced therapeutics development in Europe. With our global network of facilities and services, Cryoport Systems is a strategic partner of choice for temperature-controlled supply chain management of critical materials.